OT mobile menu

Search form


Skin Cancer / Melanoma Targets

Skin Cancer / Melanoma Targets

In this video we discuss promising results of the anti–PD-L1 agent avelumab in patients with metastatic Merkel cell carcinoma who had previously been treated with chemotherapy.

In this video we discuss 3-year overall survival data from the KEYNOTE-001 trial, which studied the anti–PD-1 antibody pembrolizumab in patients with advanced melanoma.

Inflammatory arthritis and sicca syndrome appear to be immune-related adverse events among some patients undergoing cancer treatment with the immune checkpoint inhibitors nivolumab and ipilimumab.

Trametinib, which is approved by the FDA for melanoma and other cancers, may block viral infection by stopping Merkel cell polyomavirus transcription and replication.

Details of a first-in-human case report showed that a patient with melanoma was able to achieve a durable complete response with the combination of two types of immunotherapy.

The UV radiation resistance-associated tumor suppressor gene coordinates DNA repair and might predict skin cancer risk, according to research published in the journal Molecular Cell.

It now turns out that Bim, a downstream signaling molecule of the PD-1 pathway, may hold the clue to which patients may be successful on immunotherapy for metastatic melanoma.


Subscribe to Skin Cancer / Melanoma Targets on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.